Results for: Boston Scientific

Boston Scientific’s ACURATE neo2 Aortic Valve System failed to meet its primary endpoint in the ACURATE IDE trial, resulting in a decline in the company’s stock price. The trial compared the ACURATE neo2 valve to competitor valves from Edwards Lifesciences and Medtronic, but the ACURATE neo2 failed to demonstrate non-inferiority in terms of mortality, stroke, or rehospitalization at one year. Despite this setback, the company highlighted positive results from a post-hoc analysis, and it continues to work with the FDA for U.S. approval.

Boston Scientific has temporarily halted enrollment in its AVANT GUARD trial, which is evaluating the FARAPULSE Pulsed Field Ablation (PFA) System for persistent atrial fibrillation (AFib). The pause is due to unanticipated observations in the trial, which is focusing on drug-naive patients, a population not currently indicated for PFA treatment. The company emphasizes that the observations are not life-threatening and that they remain confident in the FARAPULSE system’s overall performance.

Boston Scientific exceeded analysts’ expectations for the third quarter of 2023, reporting strong revenue growth driven by its cardiovascular segment. The company also raised its full-year 2024 guidance, but its stock dipped due to a lackluster outlook for the fourth quarter. This article provides an in-depth analysis of the company’s performance, including key financial metrics, segment growth, and future projections.

Boston Scientific Corporation (BSX) reported impressive first-quarter earnings, exceeding analyst expectations. The company’s revenue reached $3.86 billion, surpassing the estimated $3.69 billion. Sales experienced significant growth across all segments, with the cardiovascular segment leading the way with a rise of over $2.4 billion. Boston Scientific also raised its 2024 guidance, forecasting net sales growth of 11%-13% and adjusted EPS of $2.29-$2.34, both higher than previous estimates. The company’s strong performance and positive outlook contributed to a 6.02% surge in BSX shares, reaching $73.15 during Wednesday’s trading session.

Boston Scientific Corporation (NYSE: BSX) reported strong financial results for the first quarter of 2024, driven by growth in its diversified businesses. Net sales increased by 13.8% on a reported basis, 15.0% on an operational basis, and 13.1% on an organic basis compared to the prior year. The company also raised its full-year guidance, reflecting continued momentum.